Show simple item record

dc.contributor.authorPujol, Miquel
dc.contributor.authorMiró, José-María
dc.contributor.authorShaw, Evelyn
dc.contributor.authorAguado, Jose-María
dc.contributor.authorSan-Juan, Rafael
dc.contributor.authorPuig-Asensio, Mireia
dc.contributor.authorPigrau, Carles
dc.contributor.authorCalbo Sebastián, Esther
dc.contributor.authorMontejo, Miguel
dc.contributor.authorRodriguez-Álvarez, Regino
dc.contributor.authorGarcia-Pais, María-Jose
dc.contributor.authorPintado, Vicente
dc.contributor.authorEscudero-Sánchez, Rosa
dc.contributor.authorLopez-Contreras, Joaquín
dc.contributor.authorMorata, Laura
dc.contributor.authorMontero, Milagros
dc.contributor.authorAndrés, Marta
dc.contributor.authorPasquau, Juan
dc.contributor.authorArenas, María-del-Mar
dc.contributor.authorPadilla, Belén
dc.contributor.authorMurillas, Javier
dc.contributor.authorJover-Sáenz, Alfredo
dc.contributor.authorLópez-Cortes, Luis-Eduardo
dc.contributor.authorGarcía-Pardo, Graciano
dc.contributor.authorGasch, Oriol
dc.contributor.authorVidela, Sebastian
dc.contributor.authorHereu, Pilar
dc.contributor.authorTebé, Cristian
dc.contributor.authorPallarès, Natalia
dc.contributor.authorSanllorente, Mireia
dc.contributor.authorDomínguez, María-Ángeles
dc.contributor.authorCàmara, Jordi
dc.contributor.authorFerrer, Anna
dc.contributor.authorPadullés, Ariadna
dc.contributor.authorCuervo, Guillermo
dc.contributor.authorCarratalà, Jordi
dc.contributor.authorMRSA Bacteremia (BACSARM) Trial Investigators
dc.date.accessioned2021-07-02T12:31:30Z
dc.date.available2021-07-02T12:31:30Z
dc.date.issued2020
dc.identifier.citationPujol, Miquel; Miró, José-María; Shaw, Evelyn [et al.]. Daptomycin plus fosfomycin versus daptomycin alone for methicillin-resistant staphylococcus aureus bacteremia and endocarditis: a randomized clinical trial. Clinical Infectious Diseases, 2020, 72(9), p. 1517-1525. Disponible en: <https://academic.oup.com/cid/article/72/9/1517/5877897>. Fecha de acceso: 2 jul. 2021. DOI: 10.1093/cid/ciaa1081ca
dc.identifier.issn1058-4838ca
dc.identifier.urihttp://hdl.handle.net/20.500.12328/2666
dc.description.abstractBackground: We aimed to determine whether daptomycin plus fosfomycin provides higher treatment success than daptomycin alone for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia and endocarditis. Methods: A randomized (1:1) phase 3 superiority, open-label, and parallel group clinical trial of adult inpatients with MRSA bacteremia was conducted at 18 Spanish hospitals. Patients were randomly assigned to receive either 10 mg/kg of daptomycin intravenously daily plus 2 g of fosfomycin intravenously every 6 hours, or 10 mg/kg of daptomycin intravenously daily. Primary endpoint was treatment success 6 weeks after the end of therapy. Results: Of 167 patients randomized, 155 completed the trial and were assessed for the primary endpoint. Treatment success at 6 weeks after the end of therapy was achieved in 40 of 74 patients who received daptomycin plus fosfomycin and in 34 of 81 patients who were given daptomycin alone (54.1% vs 42.0%; relative risk, 1.29 [95% confidence interval, .93–1.8]; P = .135). At 6 weeks, daptomycin plus fosfomycin was associated with lower microbiologic failure (0 vs 9 patients; P = .003) and lower complicated bacteremia (16.2% vs 32.1%; P = .022). Adverse events leading to treatment discontinuation occurred in 13 of 74 patients (17.6%) receiving daptomycin plus fosfomycin, and in 4 of 81 patients (4.9%) receiving daptomycin alone (P = .018). Conclusions: Daptomycin plus fosfomycin provided 12% higher rate of treatment success than daptomycin alone, but this difference did not reach statistical significance. This antibiotic combination prevented microbiological failure and complicated bacteremia, but it was more often associated with adverse events.en
dc.format.extent9ca
dc.language.isoengca
dc.publisherOxford University Pressca
dc.relation.ispartofClinical Infectious Diseasesca
dc.relation.ispartofseries72;9
dc.rightsThis is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.comen
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject.otherEndocarditisca
dc.subject.otherBacterièmiaca
dc.subject.otherDaptomicinaca
dc.subject.otherFosfomicinaca
dc.subject.otherEstafilococ aureus resistent a la meticil·linaca
dc.subject.otherEndocarditises
dc.subject.otherBacteriemiaes
dc.subject.otherDaptomicinaes
dc.subject.otherFosfomicinaes
dc.subject.otherEstafilococo aureus resistente a la meticilinaes
dc.subject.otherEndocarditisen
dc.subject.otherBacteremiaen
dc.subject.otherDaptomycinen
dc.subject.otherFosfomycinen
dc.subject.otherMethicillin-resistant staphylococcus aureusen
dc.titleDaptomycin plus fosfomycin versus daptomycin alone for methicillin-resistant staphylococcus aureus bacteremia and endocarditis: a randomized clinical trialen
dc.typeinfo:eu-repo/semantics/articleca
dc.description.versioninfo:eu-repo/semantics/publishedVersionca
dc.rights.accessLevelinfo:eu-repo/semantics/openAccess
dc.embargo.termscapca
dc.subject.udc61ca
dc.identifier.doihttps://dx.doi.org/10.1093/cid/ciaa1081ca


Files in this item

 

This item appears in the following Collection(s)

Show simple item record

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/